Verteporfin photodynamic therapy for neovascular age-related ...

More documents

Recommendations

Info

8 Methods■■■■letters when measured with an Early Treatment Diabetic Retinopathy Study (ETDRS)distance visual acuity chart (see Outcomes).Choroidal neovascularisation must be wholly or predominantly classic (i.e. ≥ 50% of theentire lesion must consist of classic CNV).Patients with subfoveal CNV due to nAMD or any other disorder are eligible for inclusion inthe VPDT study.All patients referred for assessment at a VPDT clinic in a designated treatment centre, whethereligible or not, made up the reference population. As part of the assessment, the ophthalmologistin charge of the patient made a decision on eligibility for treatment (above). There were no apriori exclusion criteria for people in the reference population. Participating hospitals were askedto submit a full set of data at the screening visit for all ineligible patients seen in person at theVPDT clinic, together with the FA used for decision-making, irrespective of whether the FA wascarried out by the participating centre or by a referring hospital.The study population consisted of all patients treated with VPDT at participating centresirrespective of CNV aetiology. (The decision whether or not to include all patients treated withVPDT, irrespective of aetiology, was made by the SCGs.) Participants were asked to give writteninformed consent for the collection of data and use of these data for the research.Treatment with verteporfin photodynamic therapyParticipating centres were requested to classify CNV as had been done in previous RCTs 3,5,34 inorder to decide whether or not patients were eligible for treatment (Table 1).Participating centres were also requested to review patients at 3-month intervals, carrying outophthalmological and angiographic examinations to determine whether or not repeat therapywas needed. Two algorithms to guide retreatment decisions were included in the study manual(Figure 1 and Table 2). Investigators were also referred to the retreatment criteria developed by aninternational expert consensus group, the Verteporfin Round Table. 37OutcomesThe primary outcome was defined as BCVA, measured on a logMAR scale using the ETDRSdistance visual acuity chart. 38Secondary outcomes included:(a) safety, that is adverse reactions (ARs) and AEs(b) contrast sensitivity (CS) measured with the Pelli–Robson chart at 1 m 39(c) generic HRQoL measured using the Short Form questionnaire-36 items (SF-36), 40 fromwhich SF-6D scores were also derived 13(d) vision-specific HRQoL measured using the NEIVFQ 11(e) independently graded morphological changes in treated lesions, that is total lesion size, totalCNV leakage, classic leakage and fibrosis(f) health and social services (HSS) resource use measured using a custom-designedquestionnaire administered to patients at the time of hospital visits for treatment or review.Collecting data to characterise ARs and AEs was an important objective of the study because, atthe outset, there was concern that such events experienced in licensing trials of VPDT may not
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 69TABLE 1 Method for determining the category of CNV from stereoscopic FAs to help in the assessment of suitability ofpatients for treatment with VPDT according to the NICE recommendations issued in 2003 6A. Identify morphological featuresUse stereos of colour and angiographic frames to assist inrecognition of the following lesion components B. Assess total lesion size C. Categorise lesion subtype1. CNV lesion componentsFluorescein leakage associated with CNV■■Classic CNV■■Occult CNV: fibrovascular PED; late leakage of undeterminedoriginFeatures contiguous to CNV which prevent determination of theextent of leakage and which therefore constitute part of the lesion■■■■■■BloodElevated blocked fluorescence not due to blood (may be dueto RPE hyperplasia, thick exudate, fibrous tissue)Serous PED2. Other features associated with CNV which are NOT used to definethe boundaries of the lesion■■■■■■■■Atrophy: GA and non-GAFlat blocked fluorescenceFibrosis not contiguous to CNV boundaryThick exudate not contiguous to CNV boundary3. Other features which help with categorisation of CNV or whichmay modify natural history■■■■■■Retinal angiomatous proliferationChorioretinal anastamosesIdiopathic polypoidal choroidopathy1. Define the boundaries of thelesion2. Define the boundaries of thearea of classic leakage3. Estimate proportion of classicrelative to total lesion size4. Ineligible for photodynamictherapy if < 50% of lesionis CNV1. Classic with no occult(NICE FAD 1.1)1A. Classic leakage accounts for100% of lesion1B. Classic leakage accounts for50–99%, but lesion has no occultcomponent2. Predominantly classic with occult(NICE FAD 1.2)Classic leakage accounts for50–99% of lesion with someoccult3. Minimally classicClassic leakage accounts for< 50% of the lesion4. Occult with no classicClassic is 0%. Any CNV leakageis of the occult varietyGA, geographic atrophy; PED, pigment epithelial detachment; RPE, retinal pigment epithelium.The decision tree describes terminology from grading centres involved in TAP, VIP and Subfoveal Radiotherapy Study RCTs. 3,35,36(a)Belfast retreatment criteriaIs leakage present on FA?NoYesDo not treat and arrange review for 3 monthsIs leakage reduced when compared with pre-treatment?YesNoRetreat with PDTHas there been a treatmentrelatedAE?YesNoYesIs VA within six lines of last treatment?NoNo furthertherapyIf acute loss noted after treatment do not retreatFIGURE 1 Example of flow chart for making retreatment decisions – Belfast retreatment criteria. VA, visual activity.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
Page 5 and 6: DOI: 10.3310/hta16060Health Technol
Page 12 and 13: xExecutive summaryretreat on criter
Page 14 and 15: xiiExecutive summaryof data, with i
Page 16 and 17: 2 Introductionon-going or new clini
Page 18 and 19: 4 Introductionof VPDT in routine cl
Page 21: DOI: 10.3310/hta16060Health Technol
Page 31: DOI: 10.3310/hta16060Health Technol
Page 34 and 35: 20 Key changes to the protocolThese
Page 36 and 37: 22 Key changes to the protocolCentr
Page 38 and 39: 24 Key changes to the protocolADVER
Page 40 and 41: 26 Key changes to the protocolPlan
Page 42 and 43: 28 Key changes to the protocolClass
Page 44 and 45: 30 Key changes to the protocolFor i
Page 46 and 47: 32 Key changes to the protocolIn ad
Page 48 and 49: 34 Key changes to the protocolsites
Page 52 and 53: 38 Results (1) - study cohortTABLE
Page 60 and 61: 46 Results (2) - objectives A, B, C
Page 73 and 74:
DOI: 10.3310/hta16060Health Technol
Page 75 and 76:
Page 77:
Page 80 and 81:
66 Discussion of resultsStrengths a
Page 82 and 83:
68 Discussion of resultsThe VPDT st
Page 84 and 85:
70 Discussion of resultsOur analyse
Page 86 and 87:
72 Discussion of resultsA further c
Page 88 and 89:
74 Discussion of resultsVPDT. It is
Page 91 and 92:
Page 93 and 94:
Page 95:
Page 98 and 99:
84 References16. Stelmack J. Qualit
Page 100 and 101:
86 References49. Guymer RH, Chiu AW
Page 102 and 103:
88 References83. Margrain TH. Minim
Page 104 and 105:
90 Appendix 1THE VERTEPORFIN PHOTOD
Page 106 and 107:
92 Appendix 11. Overview of Manual
Page 108 and 109:
94 Appendix 1And, if also collectin
Page 110 and 111:
96 Appendix 1more patients in the v
Page 112 and 113:
98 Appendix 12.4 Limitations of the
Page 114 and 115:
100 Appendix 1Box 2 Key advantages
Page 116 and 117:
102 Appendix 14. Study population4.
Page 118 and 119:
104 Appendix 15. Recruitment to the
Page 120 and 121:
106 Appendix 16. Background data co
Page 122 and 123:
108 Appendix 1Table 1: Schedule of
Page 124 and 125:
110 Appendix 1The Verteporfin Photo
Page 126 and 127:
112 Appendix 1• Additional clinic
Page 128 and 129:
114 Appendix 18. Recording adverse
Page 130 and 131:
116 Appendix 1level of benefit from
Page 132 and 133:
118 Appendix 1• comparison of num
Page 134 and 135:
120 Appendix 110.6 Sub-group analys
Page 136 and 137:
122 Appendix 112. Data issues12.1 D
Page 138 and 139:
124 Appendix 113. Organisation13.1
Page 140 and 141:
126 Appendix 114. References[1] Ref
Page 142 and 143:
128 Appendix 1Barnes RM, Gee L, Tay
Page 144 and 145:
130 Appendix 1Appendix 1: Classifyi
Page 146 and 147:
132 Appendix 1Liverpool re-treatmen
Page 148 and 149:
134 Appendix 1Service StructurePlea
Page 150 and 151:
136 Appendix 1Has your photographer
Page 152 and 153:
138 Appendix 1There are many differ
Page 154 and 155:
140 Appendix 1testing on vision tes
Page 156 and 157:
142 Appendix 1something to do with
Page 158 and 159:
144 Appendix 1College of Ophthalmol
Page 160 and 161:
146 Appendix 1Appendix 5:Protocol f
Page 162 and 163:
148 Appendix 16.2 Subjective Refrac
Page 164 and 165:
150 Appendix 1• The patient shoul
Page 166 and 167:
152 Appendix 1Appendix 6:Protocol f
Page 168 and 169:
154 Appendix 18. It is customary to
Page 170 and 171:
156 Appendix 1Early or Transit Phas
Page 172 and 173:
158 Appendix 1
Page 174 and 175:
160 Appendix 1---------------------
Page 176 and 177:
162 Appendix 1---------------------
Page 178 and 179:
164 Appendix 1---------------------
Page 180 and 181:
166 Appendix 1Appendix 9:Site imple
Page 182 and 183:
168 Appendix 1Option 2 - units inte
Page 184 and 185:
170 Appendix 1Dos and Don’tsDosDo
Page 186 and 187:
172 Appendix 1Resource use question
Page 188 and 189:
174 Appendix 1Appendix 11: Recommen
Page 190 and 191:
176 Appendix 1ADVERSE REACTION AND
Page 192 and 193:
178 Appendix 1acute Trust; note tha
Page 194 and 195:
180 Appendix 1Ophthalmologistrespon
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203:
Page 206 and 207:
192 Appendix 3manufacturer’s pers
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 216:
FeedbackThe HTA programme and the a
show all

Verteporfin photodynamic therapy for neovascular age-related ...

Create successful ePaper yourself

Delete template?

Save as template?